Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin

Chan, Wai Man; Lam, Dennis S C; Lai, Timothy Y. Y.; Yuen, Kam‐Tong; Liu, David T.L.; Chan, Carmen K. M.; Chen, Wei Qi

doi:10.1016/s0002-9394(03)00462-8

Cited by 71 publications

(47 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequent reports have suggested that classic CNV (mainly type 2) and polypoidal lesions are possible complications of CSCR and may contribute to visual loss in these eyes. [31][32][33][34] There are even possible challenges of correctly diagnosing CNV in CSCR.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Smretschnig

Hagen

Glittenberg

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) with half-fluence rate combined with intravitreal application of anti-VEGF in treating choroidal neovascularization (CNV) in chronic central serous chorioretinopathy (CSCR). Patients and methods In this retrospective cohort study 17 consecutive patients with secondary CNV due to chronic CSCR had their diagnosis verified with fluorescein angiography (FA) and ICGA at baseline. All eyes received either intravitreal ranibizumab (IVR) or bevacizumab (IVB). On the consecutive day following the initial IVR/IVB treatment, ICGAguided verteporfin (6 mg/m 2 ) PDT with halffluence rate (25 J/cm 2 ) was performed on every patient. IVR or IVB was rescheduled on a pro re nata regimen. Main outcome measures were changes in visual acuity (VA) according to the ETDRS letter score and changes in the central foveal thickness (CFT). Results Best-corrected VA at baseline was 65.6 letters (±6.7; n = 17) according to the ETDRS letter score. At 12 months, mean ETDRS letter score improved to 71.2 letters (P = 0.34). CFT was 309 μm and decreased to 216 μm at month 12 control (P = 0.0004). Nine eyes (52.9%) received additional treatment with IVR/IVB due to recurrence of subretinal fluid, with an overall mean number of IVR/IVB treatment of 1.8 ± 3.6 per patient with no systemic side effects during 12 months' follow-up. Conclusions IVR or IVB combined with ICGA-guided half-fluence PDT with verteporfin is effective in treating CNV in chronic CSCR, with choroidal hyperpermeability in ICGA, resulting in stable vision and significant reduction of CFT.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Smretschnig

Hagen

Glittenberg

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…PDT theoretically dissipates less amount of laser thermal energy to the surrounding neurosensory retina with minimal scar formation. [15][16][17][18] It is recognized to be a noninvasive method with a high level of safety on human eyes. Cohen et al 19 recently demonstrated successful lesion involution and visual improvement after PDT in a case report.…”

Section: Discussionmentioning

confidence: 99%

“…1 PDT dissipates less amount of laser energy to surrounding neurosensory retina and retinal pigment epithelium and, theoretically, it causes an involution of the CNV, with less tissue destruction, and scar expansion. [15][16][17][18] Recently, Cohen et al 19 reported a success of PDT on three cases of juxtafoveal myopic CNV.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia—1-year results of a prospective series

Lam

Liu

Fan

et al. 2004

Eye

View full text Add to dashboard Cite

Purpose To study the efficacy of photodynamic therapy (PDT) with verteporfin in the treatment of juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia.Methods Prospective, open label, two-centre, noncomparative, interventional case series. Consecutive patients with juxtafoveal CNV associated with pathologic myopia were recruited and treated with a standard regimen of PDT with verteporfin. Patients were being followed up every 3-monthly and retreatment was considered when there was evidence of angiographic leakage. Outcome measures included changes in the mean best-corrected visual acuity (BCVA) at the 1-year follow-up when compared with the baseline, the proportion of patients who had stable (within 1 line) and improved visions. Results A total of 11 eyes from 11 patients with juxtafoveal CNV secondary to pathologic myopia were recruited and all completed the 1-year follow-up. The mean age at presentation was 44.8 years. The refractive error ranged from À6.0 to À15.0 D (7SD was À9.5573.04 D). The logMAR BCVA improved from 0.57 to 0.39 at the 1-year follow-up (Wilcoxon signed-ranks test, P ¼ 0.027). The mean improvement was 1.8 lines. Five eyes (45.4%) had BCVA improved by X3 lines. None of the treated patients had visual loss of X1 line. The mean number of treatments over the 12-month study period was 2.3 sessions. Conclusions The results are encouraging, especially on considering the low retreatment rate, stable or improved BCVA in all treated eyes, and consistently good safety profile. Juxtafoveal myopic CNV may be an expanded indication for PDT with verteporfin.

show abstract

“…These have included pharmacologic therapy, laser photocoagulation, photodynamic therapy (PDT) and most recently anti-vascular endothelial growth factor (anti-VEGF). 4,5,[7][8][9][10][11][12][13] Each study with different treatment modalities has had its own drawbacks-small population size, treatment efficacy, and adverse event occurrence. In this review, we assess the studies that evaluated the use of PDT in the treatment of CSCR.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic therapy for central serous chorioretinopathy

Erikitola

Crosby‐Nwaobi

Lotery

et al. 2014

Eye

View full text Add to dashboard Cite

Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin

Cited by 71 publications

References 39 publications

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy

Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia—1-year results of a prospective series

Photodynamic therapy for central serous chorioretinopathy

Contact Info

Product

Resources

About